The biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.
Clinical data meet preclinical validation: Axxam´s partnership with Molecular Health
Background, Latest NewsThat deserves a closer look: The recently announced partnership between Axxam S.p.A., a leading provider of integrated early discovery services, and Molecular Health GmbH, a pioneer in AI-powered data solutions for pharmaceutical R&D, is more than a standard collaboration. It exemplifies the convergence of consolidated in-vitro biology-led drug discovery with modern, data-intelligent drug development methodologies. As an example for breaking the silos of clinical and preclinical target validation.
Oncomatryx Secures EU Funding to Advance Antibody-Drug Conjugate Platform
Latest NewsSpanish biotechnology company Oncomatryx Biopharma has been selected for funding under the European Innovation Council (EIC) Accelerator, part of the EU’s Horizon Europe 2021–2027 Research and Innovation Programme. The award includes a €2.5 million grant and a €10 million equity investment, to be deployed in the company’s next financing round to proceed with the proprietary ADC platform.
Spain’s biotech: growth, impact and global role
BackgroundSpain’s biotech sector drives innovation, economic growth, and scientific excellence. With strong R&D investment, global research impact, and a leading role in gender equality, it’s a key player in health, sustainability, and strategic autonomy. BIOSPAIN 2025 in Barcelona will showcase its potential and connect global biotech leaders.
Verona Pharma: A Transatlantic Success Story in the Biotech Landscape
Latest NewsThe planned US$10 billion acquisition of UK-based Verona Pharma by US pharmaceutical giant Merck & Co. underscores several key dynamics reshaping the global biotech industry. Not only does the deal reflect Merck’s strategic push to diversify in anticipation of the looming patent expiry of its blockbuster cancer drug Keytruda, but it also highlights the growing appeal of European biotech for US investors.
AmphiStar: €12.5m EIC Funding to Advance Commercialisation of Bio-Based Surfactants
Latest NewsThe new funding includes €2.5m grant and €10m equity investment and supports Belgian AmphiStar’s potential to reshape the surfactants market. This investment will accelerate scale-up and market entry of sustainable biosurfactants, which AmphiStar has already set up transatlantic in a recent partnership.
Sino Biological Sets New Industry Standard with ProPure™ Endotoxin-Free Proteins
Sponsored PublicationsSino Biological US, Inc. proudly unveils ProPure™, an industry-leading line of ultra-pure, endotoxin-free recombinant proteins, fully produced in the USA at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas.
UK Food Standards Agency accepts Gourmey’s application for cultivated Foie Gras
Latest NewsThe British Food Standards Agency (FSA) has formally accepted an application by French start-up Gourmey SAS for regulatory approval of its cultivated foie gras, a product developed using cellular agriculture techniques. The submission was initially lodged on 26 July 2024 and was made in parallel across five jurisdictions: the European Union, United States, Singapore, Switzerland, and the United Kingdom.
First step towards scaling chemical production from CO₂
Latest NewsAs part of the green transformation of North Rhine-Westphalia’s former coal-mining region, independent assessors have recommended the co-financing of two biotechnology processes developed at pilot scale by Evonik Industries AG, with the aim of advancing them to demonstration scale. The third funding round of the “Produktives.NRW” call includes approximately €70 million from the EU’s Just Transition Fund (JTF) allocated to six projects.
Nuclidium fuels next radiopharma wave
Latest NewsBasel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
Actithera: Radiopharma Funding Gathers Huge Momentum
Latest NewsThe biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.